Modeling Multicancer Screening
- PMID: 35017194
- DOI: 10.1158/1055-9965.EPI-21-1049
Modeling Multicancer Screening
Abstract
Jiao and colleagues have developed an estimation framework for measuring the benefits of a multi-cancer screening test, notably in terms of cancer detection and deaths prevented. The approach is clear and attractive. Further developments are likely to include more flexible modeling of sensitivities and specificities.See related article by Jiao et al., p. 38.
©2022 American Association for Cancer Research.
Comment on
-
A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing.Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):38-44. doi: 10.1158/1055-9965.EPI-21-0380. Epub 2021 Sep 20. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34548329 Free PMC article.
References
-
- Bennett RL, Blanks RG. Should a standard be defined for the positive predictive value (PPV) of recall in the UK NHS Breast Screening Programme?. Breast. 2007;16:55–9.
-
- Katki HA, Bebu I. A simple framework to identify optimal cost-effective risk thresholds for a single screen: comparison to decision curve analysis. J Roy Stat Soc A. 2021;184:887–903.
-
- Duffy SW, Smith RA. The evaluation of cancer screening: concepts and outcome measures. Med Clin North Am. 2020;104:939–53.
-
- Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Stat Med. 2001;20:935–49.
-
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745–59.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
